718 related articles for article (PubMed ID: 14571813)
1. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
2. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
3. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
6. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
7. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
9. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
[TBL] [Abstract][Full Text] [Related]
11. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
12. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
[TBL] [Abstract][Full Text] [Related]
13. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
14. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
17. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
18. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
20. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
